Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

Phase 3

Completed

Conditions: Obesity
Overweight
Diabetes Mellitus, Type 2

Interventions: Drug: Placebo (semaglutide)
Drug: Semaglutide

First Posted Date: 2020-01-31

Last Posted Date: 2024-11-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 375

Registration Number: NCT04251156

Locations: 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of
🇧🇷
Instituto de Ciências Farmacêuticas de Estudos e Pesquisas, Aparecida de Goiania, Goias, Brazil
🇧🇷
CPCLIN - Centro de Pesquisas Clínicas, São Paulo, Sao Paulo, Brazil

A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens

Phase 1

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Semaglutide (administered by DV3396 pen-injector)
Drug: Semaglutide (administered by PDS290 pen-injector)

First Posted Date: 2020-01-23

Last Posted Date: 2020-11-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 111

Registration Number: NCT04238962

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide

Phase 1

Completed

Conditions: Overweight
Healthy Volunteers
Obesity

Interventions: Drug: Semaglutide

First Posted Date: 2020-01-14

Last Posted Date: 2022-01-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 28

Registration Number: NCT04228354

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in China

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Other: Insulin degludec

First Posted Date: 2020-01-13

Last Posted Date: 2024-03-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 938

Registration Number: NCT04227431

Locations: 🇨🇳
NIS-CNPC Central Hospital, Langfang, Hebei, China
🇨🇳
NIS-Langfang people's Hospital, Langfang, Hebei, China
🇨🇳
NIS-The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

and more 53 locations

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

Phase 1

Completed

Conditions: Overweight
Obesity

Interventions: Drug: NNC0174-0833

First Posted Date: 2019-12-23

Last Posted Date: 2021-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 33

Registration Number: NCT04209049

Locations: 🇺🇸
Novo Nordisk Investigational Site, Orlando, Florida, United States

A Research Study Investigating Mim8 in People With Haemophilia A

Phase 2

Completed

Conditions: Haemophilia A With or Without Inhibitors
Healthy Volunteers

Interventions: Drug: Placebo (Mim8)
Drug: NNC0365-3769 (Mim8)

First Posted Date: 2019-12-19

Last Posted Date: 2024-10-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 275

Registration Number: NCT04204408

Locations: 🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
🇺🇸
Rush University Med. Cntr, Chicago, Illinois, United States
🇺🇸
University of Iowa_Iowa City, Iowa City, Iowa, United States

and more 19 locations

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

Phase 4

Completed

Conditions: Overweight
Healthy Volunteers
Diabetes Mellitus, Type 2
Obesity

Interventions: Drug: Semaglutide
Drug: Dulaglutide

First Posted Date: 2019-12-06

Last Posted Date: 2022-11-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 104

Registration Number: NCT04189848

Locations: 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands

A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Phase 1

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Semaglutide

First Posted Date: 2019-12-05

Last Posted Date: 2021-11-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 68

Registration Number: NCT04187300

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens

Phase 1

Completed

Conditions: Healthy Volunteers
Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2019-11-05

Last Posted Date: 2021-11-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 68

Registration Number: NCT04152915

Locations: 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany

A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Phase 2

Completed

Conditions: Healthy Volunteers Overweight
Healthy Volunteers Diabetes Mellitus, Type 2
Healthy Volunteers Obesity

Interventions: Drug: Semaglutide (administered by DV3396 pen)
Drug: Semaglutide (administered by PDS290 pen)

First Posted Date: 2019-10-30

Last Posted Date: 2021-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 104

Registration Number: NCT04143945

Locations: 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy